Apotea AB (publ) APOTEA.ST
Nasdaq Stockholm · Healthcare · Pharmaceutical Retailers
104.30 SEK
+1.3%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Apotea
| SEK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 4,883 | 5,450 | 6,541 | 7,203 |
| EBITDA | 105 | 226 | 400 | 464 |
| Net income | 20 | 87 | 215 | 229 |
| Balance sheet | ||||
| Equity | 328 | 404 | 615 | 844 |
| Total debt | 333 | 262 | 242 | 331 |
| Cash | 18 | 19 | 27 | 31 |
| Net debt | 314 | 243 | 215 | 300 |
| Ratios and per share | ||||
| EBITDA margin | 2.1% | 4.1% | 6.1% | 6.4% |
| Profit margin | 0.4% | 1.6% | 3.3% | 3.2% |
| Return on equity | 6.1% | 21.6% | 34.9% | 27.1% |
| Earnings/share (SEK) | 0.19 | 0.84 | 2.06 | 2.20 |
| Book value/share (SEK) | 3.15 | 3.88 | 5.91 | 8.11 |
| Shares outstanding (M) | 104 | 104 | 104 | 104 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 47.5 |
| P/B | 12.9 |
| EV / EBITDA | 24.0 |
| Net debt / EBITDA | 0.6 |
| Return on equity | 27.1% |
| Profit margin | 3.2% |
| Beta 1Y | 0.40 |
| Revenue growth 1Y | +10.1% |
| Revenue CAGR 3Y | +13.8% |
| Earnings/share CAGR 3Y | +125.7% |
| ROE avg. 3Y | 27.9% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 0.60 |
Not investment advice. Figures may contain errors from the data source.